Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 19 |
| List of Tables | 18 | 2 |
| List of Figures | 20 | 1 |
| Introduction | 21 | 1 |
| Global Markets Direct Report Coverage | 21 | 1 |
| Pulmonary Fibrosis Overview | 22 | 1 |
| Therapeutics Development | 23 | 2 |
| Pipeline Products for Pulmonary Fibrosis Overview | 23 | 1 |
| Pipeline Products for Pulmonary Fibrosis Comparative Analysis | 24 | 1 |
| Pulmonary Fibrosis Therapeutics under Development by Companies | 25 | 6 |
| Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes | 31 | 1 |
| Pulmonary Fibrosis Pipeline Products Glance | 32 | 3 |
| Late Stage Products | 32 | 1 |
| Clinical Stage Products | 33 | 1 |
| Early Stage Products | 34 | 1 |
| Pulmonary Fibrosis Products under Development by Companies | 35 | 8 |
| Pulmonary Fibrosis Products under Investigation by Universities/Institutes | 43 | 1 |
| Pulmonary Fibrosis Companies Involved in Therapeutics Development | 44 | 74 |
| AdAlta Pty Ltd. | 44 | 1 |
| Advinus Therapeutics Ltd | 45 | 1 |
| Aeolus Pharmaceuticals, Inc. | 46 | 1 |
| Afferent Pharmaceuticals, Inc. | 47 | 1 |
| Angion Biomedica Corp. | 48 | 1 |
| Apellis Pharmaceuticals Inc | 49 | 1 |
| Asahi Kasei Pharma Corp. | 50 | 1 |
| aTyr Pharma, Inc. | 51 | 1 |
| Biogen Inc | 52 | 1 |
| Bioneer Corporation | 53 | 1 |
| BiOrion Technologies B.V. | 54 | 1 |
| Bristol-Myers Squibb Company | 55 | 1 |
| Celgene Corporation | 56 | 1 |
| Chrysalis Pharma SAS | 57 | 1 |
| Clanotech AB | 58 | 1 |
| Compugen Ltd. | 59 | 1 |
| Cynata Therapeutics Limited | 60 | 1 |
| Diffusion Pharmaceuticals Inc. | 61 | 1 |
| Digna Biotech, S.L. | 62 | 1 |
| Elsalys Biotech SAS | 63 | 1 |
| F. Hoffmann-La Roche Ltd. | 64 | 1 |
| FibroGen, Inc. | 65 | 1 |
| FibroStatin SL | 66 | 1 |
| Galapagos NV | 67 | 1 |
| Galectin Therapeutics, Inc. | 68 | 1 |
| GenKyoTex S.A. | 69 | 1 |
| GlaxoSmithKline Plc | 70 | 1 |
| Global Blood Therapeutics, Inc. | 71 | 1 |
| GNI Group Ltd. | 72 | 1 |
| HEC Pharm Co., Ltd. | 73 | 1 |
| Histocell S.L. | 74 | 1 |
| Hydra Biosciences, Inc. | 75 | 1 |
| iBio, Inc. | 76 | 1 |
| Immunomet Therapeutics, Inc. | 77 | 1 |
| Inventiva | 78 | 1 |
| Isarna Therapeutics GmbH | 79 | 1 |
| Kadmon Corporation, LLC | 80 | 1 |
| Kasiak Research Private Limited | 81 | 1 |
| KineMed, Inc. | 82 | 1 |
| Kolltan Pharmaceuticals, Inc. | 83 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 84 | 1 |
| Lpath, Inc. | 85 | 1 |
| Lung Therapeutics, Inc | 86 | 1 |
| miRagen Therapeutics, Inc. | 87 | 1 |
| Moerae Matrix, Inc. | 88 | 1 |
| MorphoSys AG | 89 | 1 |
| NicOx S.A. | 90 | 1 |
| Nitto Denko Corporation | 91 | 1 |
| Novartis AG | 92 | 1 |
| Nuevolution AB | 93 | 1 |
| Pharmaxis Limited | 94 | 1 |
| Pharmicell Co., Ltd. | 95 | 1 |
| Pluristem Therapeutics Inc. | 96 | 1 |
| Promedior, Inc. | 97 | 1 |
| ProMetic Life Sciences Inc. | 98 | 1 |
| Pulmatrix, Inc. | 99 | 1 |
| RedHill Biopharma Ltd. | 100 | 1 |
| Respira Therapeutics Inc | 101 | 1 |
| Rhizen Pharmaceuticals S.A. | 102 | 1 |
| Ribomic Inc. | 103 | 1 |
| Saje Pharma, LLC | 104 | 1 |
| Sanofi | 105 | 1 |
| Sirnaomics, Inc. | 106 | 1 |
| Sorrento Therapeutics, Inc. | 107 | 1 |
| SPR Biosciences LLC | 108 | 1 |
| Symic Biomedical, Inc. | 109 | 1 |
| TaiwanJ Pharmaceuticals Co., Ltd. | 110 | 1 |
| Terpenoid Therapeutics, Inc. | 111 | 1 |
| Teva Pharmaceutical Industries Ltd. | 112 | 1 |
| Therabron Therapeutics, Inc. | 113 | 1 |
| Vault Pharma Inc. | 114 | 1 |
| Vericel Corporation | 115 | 1 |
| Vicore Pharma AB | 116 | 1 |
| Yuhan Corporation | 117 | 1 |
| Pulmonary Fibrosis Therapeutics Assessment | 118 | 15 |
| Assessment by Monotherapy Products | 118 | 1 |
| Assessment by Target | 119 | 5 |
| Assessment by Mechanism of Action | 124 | 5 |
| Assessment by Route of Administration | 129 | 2 |
| Assessment by Molecule Type | 131 | 2 |
| Drug Profiles | 133 | 227 |
| AB-22 Drug Profile | 133 | 1 |
| ABC-294640 Drug Profile | 134 | 5 |
| acALY-18 Drug Profile | 139 | 1 |
| AD-114 Drug Profile | 140 | 1 |
| AEOL-10150 Drug Profile | 141 | 9 |
| AF-219 Drug Profile | 150 | 4 |
| Altepan Drug Profile | 154 | 1 |
| AM-0010 Drug Profile | 155 | 2 |
| Antisense RNAi Oligonucleotide for COPD and IPF Drug Profile | 157 | 1 |
| APL-1 Drug Profile | 158 | 1 |
| BB-3 Drug Profile | 159 | 4 |
| BG-00011 Drug Profile | 163 | 1 |
| BMS-986020 Drug Profile | 164 | 1 |
| BOT-191 Drug Profile | 165 | 1 |
| C-21 Drug Profile | 166 | 2 |
| CC-90001 Drug Profile | 168 | 1 |
| Cellgram-Lung Drug Profile | 169 | 1 |
| CG-1011 Drug Profile | 170 | 1 |
| CGEN-25009 Drug Profile | 171 | 1 |
| CLT-28643 Drug Profile | 172 | 1 |
| CM-101 Drug Profile | 173 | 1 |
| CT-140 Drug Profile | 174 | 1 |
| CT-365 Drug Profile | 175 | 1 |
| D-9030 Drug Profile | 176 | 1 |
| DB-02901 Drug Profile | 177 | 1 |
| digeranyl bisphosphonate Drug Profile | 178 | 1 |
| disitertide Drug Profile | 179 | 2 |
| Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis Drug Profile | 181 | 1 |
| Drugs for Idiopathic Pulmonary Fibrosis Drug Profile | 182 | 1 |
| Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis Drug Profile | 183 | 1 |
| FSMAB-26 Drug Profile | 184 | 1 |
| FSSME-12 Drug Profile | 185 | 1 |
| GBT-1118 Drug Profile | 186 | 1 |
| GBT-440 Drug Profile | 187 | 3 |
| GKT-831 Drug Profile | 190 | 3 |
| GLPG-1690 Drug Profile | 193 | 2 |
| GLPG-2938 Drug Profile | 195 | 1 |
| GRMD-02 Drug Profile | 196 | 11 |
| Grx1-iSPERSE Drug Profile | 207 | 1 |
| GSK-3008348 Drug Profile | 208 | 1 |
| HC-067047 Drug Profile | 209 | 1 |
| HEC-585 Drug Profile | 210 | 1 |
| HR-017 Drug Profile | 211 | 1 |
| IBIOCFB-03 Drug Profile | 212 | 2 |
| ICG-001 Drug Profile | 214 | 1 |
| IM-156 Drug Profile | 215 | 1 |
| iMod.Fc Drug Profile | 216 | 1 |
| ISTH-0047 Drug Profile | 217 | 2 |
| ITMN-10534 Drug Profile | 219 | 1 |
| ITMN-14440 Drug Profile | 220 | 1 |
| ITMN-30162 Drug Profile | 221 | 1 |
| IVA-337 Drug Profile | 222 | 1 |
| ixmyelocel-T Drug Profile | 223 | 6 |
| JKB-117 Drug Profile | 229 | 1 |
| JKB-119 Drug Profile | 230 | 1 |
| KAR-5585 Drug Profile | 231 | 1 |
| KBP-7018 Drug Profile | 232 | 1 |
| KD-025 Drug Profile | 233 | 4 |
| KTN-0158 Drug Profile | 237 | 2 |
| lebrikizumab Drug Profile | 239 | 3 |
| Lpathomab Drug Profile | 242 | 3 |
| LTI-03 Drug Profile | 245 | 1 |
| M-10 Drug Profile | 246 | 1 |
| MGN-4220 Drug Profile | 247 | 1 |
| MMI-0100 Drug Profile | 248 | 2 |
| Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD Drug Profile | 250 | 1 |
| Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis Drug Profile | 251 | 1 |
| MOR-107 Drug Profile | 252 | 1 |
| NAS-911 Drug Profile | 253 | 2 |
| NCX-466 Drug Profile | 255 | 1 |
| ND-L02s0201 Drug Profile | 256 | 2 |
| Neumomir Drug Profile | 258 | 1 |
| noscapine Drug Profile | 259 | 1 |
| NUE-7770 Drug Profile | 260 | 1 |
| Oligonucleotides for Respiratory, Oncology and Infectious Disease Drug Profile | 261 | 1 |
| OLX-101 Drug Profile | 262 | 1 |
| OLX-201 Drug Profile | 263 | 1 |
| omipalisib Drug Profile | 264 | 1 |
| P-007 Drug Profile | 265 | 1 |
| P-013 Drug Profile | 266 | 1 |
| pamrevlumab Drug Profile | 267 | 6 |
| PBF-1129 Drug Profile | 273 | 1 |
| PBI-4050 Drug Profile | 274 | 5 |
| PBI-4425 Drug Profile | 279 | 1 |
| Peptide to Target C/EBP-Beta for Lung Fibrosis Drug Profile | 280 | 1 |
| pirfenidone Drug Profile | 281 | 2 |
| pirfenidone Drug Profile | 283 | 1 |
| PLX-PAD Drug Profile | 284 | 8 |
| PNQ-103 Drug Profile | 292 | 1 |
| PRI-724 Drug Profile | 293 | 2 |
| PRM-151 Drug Profile | 295 | 5 |
| PUR-1500 Drug Profile | 300 | 1 |
| PXS-4820 Drug Profile | 301 | 1 |
| RBM-005 Drug Profile | 302 | 1 |
| RBM-006 Drug Profile | 303 | 1 |
| Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation Drug Profile | 304 | 1 |
| Recombinant Peptides for Fibrosis Drug Profile | 305 | 1 |
| Recombinant Protein for Inflammation and Pulmonary Fibrosis Drug Profile | 306 | 1 |
| Refacell-IPF Drug Profile | 307 | 1 |
| RES-529 Drug Profile | 308 | 4 |
| RP-182 Drug Profile | 312 | 1 |
| RP-3128 Drug Profile | 313 | 1 |
| RP-6503 Drug Profile | 314 | 1 |
| RT-234 Drug Profile | 315 | 1 |
| SAR-156597 Drug Profile | 316 | 1 |
| SB-300 Drug Profile | 317 | 1 |
| SD-560 Drug Profile | 318 | 1 |
| SM-04646 Drug Profile | 319 | 1 |
| Small Molecule for Idiopathic Pulmonary Fibrosis Drug Profile | 320 | 1 |
| Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile | 321 | 1 |
| Small Molecules for COPD and IPF Drug Profile | 322 | 1 |
| Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 323 | 1 |
| Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 324 | 1 |
| Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis Drug Profile | 325 | 1 |
| Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis Drug Profile | 326 | 1 |
| Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis Drug Profile | 327 | 1 |
| Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis Drug Profile | 328 | 1 |
| Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis Drug Profile | 329 | 1 |
| Small Molecules to Inhibit MRTF and SRF for Idiopathic Pulmonary Fibrosis Drug Profile | 330 | 1 |
| Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis Drug Profile | 331 | 1 |
| SPL-334 Drug Profile | 332 | 1 |
| SPL-334.1 Drug Profile | 333 | 1 |
| SPL-891.1 Drug Profile | 334 | 1 |
| Stem Cell Therapy for Idiopathic Lung Fibrosis Drug Profile | 335 | 1 |
| Stem Cell Therapy for Idiopathic Lung Fibrosis and Asthma Drug Profile | 336 | 1 |
| Stem Cell Therapy for Idiopathic Pulmonary Fibrosis Drug Profile | 337 | 1 |
| STP-705 Drug Profile | 338 | 2 |
| Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders Drug Profile | 340 | 1 |
| Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology Drug Profile | 341 | 2 |
| TD-139 Drug Profile | 343 | 1 |
| thrombomodulin alfa Drug Profile | 344 | 2 |
| tipelukast Drug Profile | 346 | 5 |
| TM-5441 Drug Profile | 351 | 1 |
| vismodegib Drug Profile | 352 | 5 |
| VPI-131 Drug Profile | 357 | 1 |
| YH-siRNA1 Drug Profile | 358 | 1 |
| ZL-2102 Drug Profile | 359 | 1 |
| Pulmonary Fibrosis Dormant Projects | 360 | 7 |
| Pulmonary Fibrosis Discontinued Products | 367 | 1 |
| Pulmonary Fibrosis Product Development Milestones | 368 | 8 |
| Featured News &Press Releases | 368 | 1 |
| Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys s Dutch Lanthipeptide Subsidiary | 368 | 1 |
| Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016 | 368 | 1 |
| Sep 14, 2016: Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders | 368 | 1 |
| Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate | 369 | 1 |
| Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis | 369 | 1 |
| Aug 03, 2016: FibroStatin Announces Breakthrough in the Fight Against Drug-Resistant Cancer and Fibrosis. Novel Treatment Inhibits the Epithelial-Mesenchymal Transition (EMT), a Key Underlying Pathology Contributing to These Diseases | 370 | 1 |
| Aug 03, 2016: GNI Subsidiary Receives Approval for Etuary 200mg Capsule | 371 | 1 |
| Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF | 372 | 1 |
| Jul 24, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis | 372 | 1 |
| Jul 11, 2016: Initiation of Drug Development for Oncology Using Nitto s Proprietary DDS Platform | 372 | 1 |